In our centre distal ureteral frozen sections during radical cystectomy (RC) for bladder cancer (BC) are routinely performed and repeated, if positive, until the reach of negative samples.
INTRODUCTION AND OBJECTIVES:
In our centre distal ureteral frozen sections during radical cystectomy (RC) for bladder cancer (BC) are routinely performed and repeated, if positive, until the reach of negative samples.
However, despite several studies, there is not a global consensus on the adequate management of positive margins. Especially it is not clear if the positive findings are correlated with oncological outcomes. Aim of our study was to evaluate if the presence of positive ureteral frozen sections (negative at final pathological report) impacts on recurrence and survival outcomes METHODS: We evaluated 391 consecutive patients treated with RC for BC at a single tertiary referral centre between 2008 and 2015. We systematically performed ureteral frozen section independently to the bladder diversion or to TNM status. Univariable and multivariable Cox proportional hazards regression model was used to predict cancer specific mortality (CSM), overall mortality (OM) and recurrence (R). The Kaplan-Meier method was used to compare recurrence, CSM and OM in the overall population. Covariates included age at surgery, gender, pathological T stage, pathological N stage, pathological grade, surgical margins (SM) and lymph vascular invasion (LVI) RESULTS: Median age was 71 years (IQR 40-90 years). 322 patients (82%) were male. Overall, 117 (29,9%), 51(13%) and 174 (44,5%) patients were recorded with lymph node metastases, positive SM and pT3-4 , respectively. CSM was observed in 146 (37%) patients, whereas OM was observed in 194 patients (49%) and R in 154 (39%) patients. Median follow-up was 30 months (IQR 5-109 months).
Intraoperative frozen section were positive in 62 (16%) patients. At univariate analysis presence of positive frozen section was associated with CSM and R (respectively HR 1,82 and 1. 
MP38-16 JUSTIFICATION OF 8TH EDITION AJCC TUMOR NODE METASTASIS UPDATES FOR BLADDER CANCER STAGING
Marcus Daniels*, Trinity Bivalacqua, Andres Matoso, Max Kates, Baltimore, MD INTRODUCTION AND OBJECTIVES: In 2017, the AJCC updated guidelines for the staging of bladder cancer. The new guidelines subdivided prognostic stage groups 3 and 4 into four groups based on regional lymph node (LN) and metastasis location. In the 7th edition, T3A-T4A N0 M0 were group 3 while group 4 included T4B, N1-3, and M1 patients. In the 8th Edition guidelines: group 3A includes T3A-T4A and N1 patients, group 3B includes N2-3 patients, group 4A includes T4B and M1A patients, and group 4B includes M1B patients. We sought to justify these changes in our institutional cohort.
METHODS: We retrospectively identified radical cystectomy patients with T3A-T4B N0 M0 disease and patients with N1-3 disease at our institution (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Eight or more LN removed was considered appropriate to determine LN status. Patients were stratified according to AJCC 7th and 8th Edition staging. Baseline differences in demographics were compared and Kaplan-Meier curves were constructed to assess recurrence free survival (RFS) and overall survival (OS) between groups. Recurrence was considered unknown if follow up time was less than 1 month.
RESULTS: A total of 333 patients were included in the analysis. No T4B, N3, nor M1 patients were included due to limited sample size. Median LN removed was 18. Median follow-up time was 23.5 months. Demographics were similar between groups. Seventh edition Group 3 (n[153) and Group 4 (n[180) patients differed significantly in RFS (p[ 0.032) and OS (p[ 0.004). Eighth edition Group 3A (n[222) and Group 3B (n[111) patients differed in respect to RFS (p< 0.001) and OS (p< 0.001).
CONCLUSIONS: The 8th edition AJCC guidelines more accurately predict RFS and OS in muscle invasive and LN positive bladder cancer compared to the 7th edition guidelines. Specifically, characterizing N1-3 as Stage 3 and different from metastatic, Stage 4 disease, while differentiating solitary positive pelvic LN (Stage 3a) from multiple or distal positive LN (Stage 3b) more accurately prognosticates bladder cancer patients after cystectomy.
